File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.amjcard.2008.08.057
- Scopus: eid_2-s2.0-58149464826
- PMID: 19121436
- WOS: WOS:000262564300010
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Paclitaxel-Eluting Stent Long-Term Outcomes in Percutaneous Saphenous Vein Graft Interventions (PELOPS) Study
Title | Paclitaxel-Eluting Stent Long-Term Outcomes in Percutaneous Saphenous Vein Graft Interventions (PELOPS) Study |
---|---|
Authors | |
Issue Date | 2009 |
Publisher | Excerpta Medica, Inc.. The Journal's web site is located at http://www.ajconline.org/ |
Citation | American Journal Of Cardiology, 2009, v. 103 n. 2, p. 199-202 How to Cite? |
Abstract | This study examined the 1-year clinical and angiographic follow-up results of implantation of paclitaxel-eluting stents (PES) in aortocoronary saphenous vein graft (SVG) lesions. Sixty-eight consecutive patients with 90 nonoccluded SVG lesions were treated with PES (Taxus), size ranging from 2.25 to 4.5 mm. Angiographic follow-up was performed on 63 patients (93%) and 83 lesions (92%) at 12 months; major adverse cardiac event (MACE) was recorded in all patients at 1 year. The mean age of patients was 71 ± 8 years with predominance of men (75%); the mean graft age was 13 ± 4 years. Glycoprotein IIb/ IIIa inhibitors were given in 21 patients (31%); embolic protection devices were used in 54 lesions (60%). On average, patients received 1.4 stents per lesion with a stent size of 3.4 ± 0.6 mm and a length of 35.8 ± 27.0 mm. Angiographic follow-up revealed a late loss of 0.36 ± 0.66 mm with an in-segment binary restenosis rate of 7%. The in-hospital MACE was 7%, which was solely contributed by 5 patients with postprocedure non-Q myocardial infarction; the 1-year MACE was 15%, accounted by 1 noncardiac death and 9 patients with target vessel revascularization. Peripheral vascular disease and the use of glycoprotein IIb/ IIIa inhibitors were the independent predictors of MACE at 1 year. In conclusion, implantation of PES to treat degenerative aortocoronary SVG lesions is safe and associated with low late loss, angiographic restenosis, and MACE at 1-year follow-up. © 2009 Elsevier Inc. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/59163 |
ISSN | 2023 Impact Factor: 2.3 2023 SCImago Journal Rankings: 0.950 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jim, MH | en_HK |
dc.contributor.author | Ho, HH | en_HK |
dc.contributor.author | Ko, RLy | en_HK |
dc.contributor.author | Yiu, KH | en_HK |
dc.contributor.author | Siu, CW | en_HK |
dc.contributor.author | Lau, CP | en_HK |
dc.contributor.author | Chow, WH | en_HK |
dc.date.accessioned | 2010-05-31T03:44:06Z | - |
dc.date.available | 2010-05-31T03:44:06Z | - |
dc.date.issued | 2009 | en_HK |
dc.identifier.citation | American Journal Of Cardiology, 2009, v. 103 n. 2, p. 199-202 | en_HK |
dc.identifier.issn | 0002-9149 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/59163 | - |
dc.description.abstract | This study examined the 1-year clinical and angiographic follow-up results of implantation of paclitaxel-eluting stents (PES) in aortocoronary saphenous vein graft (SVG) lesions. Sixty-eight consecutive patients with 90 nonoccluded SVG lesions were treated with PES (Taxus), size ranging from 2.25 to 4.5 mm. Angiographic follow-up was performed on 63 patients (93%) and 83 lesions (92%) at 12 months; major adverse cardiac event (MACE) was recorded in all patients at 1 year. The mean age of patients was 71 ± 8 years with predominance of men (75%); the mean graft age was 13 ± 4 years. Glycoprotein IIb/ IIIa inhibitors were given in 21 patients (31%); embolic protection devices were used in 54 lesions (60%). On average, patients received 1.4 stents per lesion with a stent size of 3.4 ± 0.6 mm and a length of 35.8 ± 27.0 mm. Angiographic follow-up revealed a late loss of 0.36 ± 0.66 mm with an in-segment binary restenosis rate of 7%. The in-hospital MACE was 7%, which was solely contributed by 5 patients with postprocedure non-Q myocardial infarction; the 1-year MACE was 15%, accounted by 1 noncardiac death and 9 patients with target vessel revascularization. Peripheral vascular disease and the use of glycoprotein IIb/ IIIa inhibitors were the independent predictors of MACE at 1 year. In conclusion, implantation of PES to treat degenerative aortocoronary SVG lesions is safe and associated with low late loss, angiographic restenosis, and MACE at 1-year follow-up. © 2009 Elsevier Inc. All rights reserved. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Excerpta Medica, Inc.. The Journal's web site is located at http://www.ajconline.org/ | en_HK |
dc.relation.ispartof | American Journal of Cardiology | en_HK |
dc.subject.mesh | Aged | en_HK |
dc.subject.mesh | Coronary Angiography | en_HK |
dc.subject.mesh | Coronary Artery Bypass | en_HK |
dc.subject.mesh | Coronary Disease - radiography - therapy | en_HK |
dc.subject.mesh | Drug-Eluting Stents | en_HK |
dc.subject.mesh | Female | en_HK |
dc.subject.mesh | Humans | en_HK |
dc.subject.mesh | Logistic Models | en_HK |
dc.subject.mesh | Male | en_HK |
dc.subject.mesh | Paclitaxel - administration & dosage | en_HK |
dc.subject.mesh | Proportional Hazards Models | en_HK |
dc.subject.mesh | Prospective Studies | en_HK |
dc.subject.mesh | Saphenous Vein - transplantation | en_HK |
dc.subject.mesh | Treatment Outcome | en_HK |
dc.subject.mesh | Tubulin Modulators - administration & dosage | en_HK |
dc.title | Paclitaxel-Eluting Stent Long-Term Outcomes in Percutaneous Saphenous Vein Graft Interventions (PELOPS) Study | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Yiu, KH:khkyiu@hku.hk | en_HK |
dc.identifier.email | Siu, CW:cwdsiu@hkucc.hku.hk | en_HK |
dc.identifier.authority | Yiu, KH=rp01490 | en_HK |
dc.identifier.authority | Siu, CW=rp00534 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.amjcard.2008.08.057 | en_HK |
dc.identifier.pmid | 19121436 | - |
dc.identifier.scopus | eid_2-s2.0-58149464826 | en_HK |
dc.identifier.hkuros | 153472 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-58149464826&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 103 | en_HK |
dc.identifier.issue | 2 | en_HK |
dc.identifier.spage | 199 | en_HK |
dc.identifier.epage | 202 | en_HK |
dc.identifier.isi | WOS:000262564300010 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Jim, MH=6603860344 | en_HK |
dc.identifier.scopusauthorid | Ho, HH=7401465369 | en_HK |
dc.identifier.scopusauthorid | Ko, RLy=15020468300 | en_HK |
dc.identifier.scopusauthorid | Yiu, KH=35172267800 | en_HK |
dc.identifier.scopusauthorid | Siu, CW=7006550690 | en_HK |
dc.identifier.scopusauthorid | Lau, CP=35275317200 | en_HK |
dc.identifier.scopusauthorid | Chow, WH=7402281062 | en_HK |
dc.identifier.issnl | 0002-9149 | - |